Baynes Roy D. 4
4 · Eikon Therapeutics, Inc. · Filed Mar 4, 2026
Insider Transaction Report
Form 4
Baynes Roy D.
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-03-02+134,088→ 134,088 totalExercise: $14.88Exp: 2036-03-01→ Common Stock (134,088 underlying)
Footnotes (1)
- [F1]1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Signature
/s/ Benjamin Thorner, Attorney-in-Fact|2026-03-04